
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
SchizophreniaCentral Nervous System Diseases1 moreThis study is being conducted to determine the safety and effect on cognitive function of two different doses of an investigational medication, EVP-6124, in individuals with schizophrenia who are on chronic stable atypical anti-psychotic therapy. In addition, behavioral and psychotic symptoms will be evaluated.

pRESET for Occlusive Stroke Treatment
Brain DiseasesCardiovascular Diseases10 moreCompare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion

Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)
StrokeAcute5 moreOur primary aim is to investigate whether remote ischemic conditioning (RIC) as an adjunctive treatment can improve long-term recovery in acute stroke patients as an adjunct to standard treatment.

Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia...
Schizophrenia; PsychosisMetabolic Syndrome6 moreFute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients. This study is the first clinical trial to explore the treatment of patients with flupentixol combined with MARTAs. However, due to research limitations, the number of patients who participated in the clinical trial is small, and it depends on subsequent larger-scale clinical trials for more in-depth verification.

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants...
Alzheimer's DiseaseCognitive Impairment5 moreThis study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with early Alzheimer's Disease.

Mindfulness-based Intervention to Promote Psychological Wellbeing in People With Epilepsy
EpilepsyBrain Diseases2 moreThe efficacy of mindfulness-based intervention (MBI) for epilepsy has yet to be thoroughly investigated. Hence, the aim of the present study is to examine the effects of MBI on the psychological wellbeing of people with epilepsy (PWE) using a randomized trial design. Key outcomes include depression, anxiety and quality of life. Our primary objective was to evaluate the effect of mindfulness-based therapy on anxiety, depression, epilepsy specific QOL, and life satisfaction in PWE, applying the concept of Reliable Change Index. The secondary objective was to assess whether the results correlate with the level of mindfulness. Study results may be used to decide whether it is worth offering mindfulness training for PWE as an alternative therapy to cope and improve seizure management.

Intelligent Activity-based Client-centred Training
Central Nervous System DiseasesAgedThe purpose of this study is to determine whether additional therapy with i-ACT system is effective in the training of functional skills in persons with central neurological diseases (e.g. multiple sclerosis, stroke, spinal cord injury, etc.).

Sub-study to Spinal Cord Stimulation to Restore Cough
Spinal Cord InjuriesSpinal Cord Diseases3 moreEvaluation of Wire Electrodes to Activate the Expiratory Muscles to Restore Cough

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT)...
Brain DiseasesBrain Neoplasms3 moreThis Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
Parkinson DiseaseNeurodegenerative Diseases3 moreThe purpose of this study is to assess the long term safety of SCH 420814 (preladenant) in participants with moderate to severe Parkinson's Disease who are taking an L-Dopa/dopa decarboxylase inhibitor and/or dopamine agonist. All participants must have participated in the main study (P04501; NCT00406029) entitled "A Phase 2, 12 Week, Double Blind, Dose Finding, Placebo Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias."